MK-4830

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Colorectal CancerSmall Cell Lung CancerEsophageal Squamous Cell CarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

1

Vectibix

Amgen

Phase 3

322

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

373

Bayer Aspirin

Bayer

Phase 3

74

Mitosol

UUroGen Pharma Ltd.

Phase 3

15

Telisotuzumab Adizutecan

AbbVie

Phase 3

26

Calcium Folinate

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

37

Folfirinox

PPhanes Therapeutics

Phase 3

18

Iron Isomaltoside

TThomas Jefferson University

Phase 3

39

Tucidinostat

CChipscreen Biosciences, Ltd.

Phase 3

110

Mfolfoxiri

DDominik Paul Modest

Phase 3

3Show 39 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Recruiting·Merck & Co.·Phase 1/2·NCT04938817·110 enrolled

A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)

Completed·Merck & Co.·Phase 2·NCT04924101·122 enrolled

Carcinoma, Non-Small-Cell Lung2 trials

KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)

Recruiting·Merck & Co.·Preclinical·NCT04165070·450 enrolled

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

Completed·Merck & Co.·Phase 2·NCT04165096·128 enrolled

Non-Small Cell Lung Cancer1 trial

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

Completed·Merck & Co.·Phase 2·NCT04165083·102 enrolled

Advanced Solid Tumors1 trial

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Completed·Merck & Co.·Phase 1·NCT03564691·470 enrolled

Esophageal Cancer1 trial

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Completed·Merck & Co.·Phase 1/2·NCT05342636·90 enrolled

5 more indications

Ovarian Cancer1 trial

Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

Completed·Merck & Co.·Phase 2·NCT05446870·160 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Recruiting·Merck & Co.·Preclinical·NCT05319730·230 enrolled

Melanoma1 trial

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C

Completed·Merck & Co.·Preclinical·NCT04303169·146 enrolled

Carcinoma, Renal Cell1 trial

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03B in Second-Line Metastatic Participants

Active, not recruiting·Merck & Co.·Preclinical·NCT04626518·370 enrolled

Colorectal Cancer1 trial

A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)

Active, not recruiting·Merck & Co.·Phase 2·NCT04895722·302 enrolled

Details

Drug Info

Related News